Simulations Plus Faces Securities Investigation Amid Guidance Cuts and Auditor Dismissal
Event summary
- Johnson Fistel investigates Simulations Plus for potential securities law violations related to financial reporting and internal controls.
- Simulations Plus cut fiscal 2025 revenue guidance by $14M–$17M on June 11, 2025, citing market uncertainties in pharma/biotech sectors.
- Stock dropped 24% following guidance revision and another 26% after Q3 loss disclosure and auditor dismissal (July 14–15, 2025).
- Grant Thornton disputed Simulations Plus' disclosures, citing unresolved issues on segment reporting and internal controls.
The big picture
Simulations Plus' rapid guidance cuts and auditor fallout highlight risks in specialized software providers serving volatile biotech markets. The case underscores growing scrutiny over financial controls in mid-cap tech firms, where revenue visibility is critical for valuation multiples. Johnson Fistel's investigation signals potential class-action exposure if misconduct allegations gain traction.
What we're watching
- Governance Dynamics
- How Simulations Plus' leadership addresses auditor disputes and internal control weaknesses will shape investor confidence.
- Regulatory Scrutiny
- Whether SEC involvement escalates following Grant Thornton's public disagreement with the company's disclosures.
- Market Positioning
- The pace at which Simulations Plus stabilizes pharma/biotech customer relationships amid budget constraints and project delays.
Related topics